ArcticZymes Technologies — Director's Dealing 2017

May 8, 2017

Biotec Pharmacon - Mandatory notification of trade

Biotec Pharmacon - Mandatory notification of trade

(Tromsø 8. May 2017) Stuart Devine, VP Marketing in Biotec Betaglucans AS has

today purchased 20.000 shares in Biotec Pharmacon at NOK 6,14 per share. After

this transaction, Stuart Devine and associates hold 45.187 shares and 30.000

options in Biotec Pharmacon.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact

Børge Sørvoll

CFO

+47 952 90 187

borge.sorvoll@biotec.no